No answer. this stock has always been erratic, but more so recently. Hopefully not becoming the plaything a HFT hedgie. Wouldn't seem to be enough float but you never know.
snag you say? hope you're right. if not I'll happily take +10% a day. That could help fill in this hole I'm looking at.
The SP is in the toilet right now, which is also a good time to cover if you're short.. No need to manipulate with inside info, just harvest.
Classic FUD...that's all.. Drossman is the most transparent basher on here. Total amateur, makes wonder why someone would pay him at all for this garbage.
You're probably right. The thing for me is making money. And that seems increasingly elusive in most of my public bio tech plays.
hey, its Eeyore!
Why so down in the mouth donkey boy? Cheer up, life is good. Just be glad you have no position in this stock and instead just do freelance PR for god knows who. What a wah-wonderful career you have! As Poo-bear never said "life is short, so do childish PR for the shorts!".
Good research. But I'm not sure we should jump to conclusions. I'm no expert on SNY, but are any of the products they list as nascent as afrezza ? My point is, if it's not perceived as a big and immediate revenue center for SNY, it wouldn't make sense to overstate its importance in the lineup...at this time. Not trying to be optimistic, just imagining SNY's priorities. Imagine if Google came out and said a top priority was monetizing a completely unprofitable and expetimental product within Google X? They would get slammed and management's decision-making would be questioned....for good reason!